Inovio Pharmaceuticals Inc. has gained a poor reputation with many biotech investors, being seen as a company which in recent years has pledged to develop vaccines against a string of novel virus outbreaks – MERS, Zika and Ebola – but failed to deliver on its promises.
Inovio Confirms Frontrunner Status In COVID-19 Vaccine Race, But Can It Prove Skeptics Wrong?
Interview: CEO Says He Welcomes Scrutiny, Competition
Its ‘virus chasing’ habits has given Inovio a bad reputation. But with backing from CEPI and Bill Gates, it has a chance to prove the doubters wrong.
